Chimeric: Media Thread, page-89

Well Said again, I recall Carl June ( inventor of Car-t for those new) stating in a solid tumor YouTube video that most Car-T pre clinical mouse trial results essentially mean nothing until you do phase I human trials. You can’t truly measure safety i.e neurotoxicity or cytokine storm in mice you have to get it in humans. However, this is a statement from the pre-clinical CLTX study.

“Our study thus establishes that the intrinsic binding properties of a natural toxin peptide can be exploited in generating targeted CAR T cells,” the authors concluded. “This study demonstrates that CLTX, a peptide component of scorpion venom, can be successfully incorporated into a CAR construct to redirect cytotoxic T cells to target GBMs.” And, as the team further noted, although the mouse models may only represent a surrogate for human safety, they still provide relevant information about off-tumor targeting. “Using these preclinical models, we determined that systemic (intravenous) and regional (ICT and ICV) delivery of CLTX-CAR T cells into both healthy and tumor-bearing mice did not show systemic toxicity.” The investigators say their combined results provide “strong evidence” for efficacy, together with negligible off tumor toxicity, and so “support future clinical evaluation in patients with GBM.”

https://www.genengnews.com/news/brain-cancer-car-t-cell-therapy-guided-by-scorpion-toxin-starts-first-human-trial/

To achieve safety and any sort of efficacy in the first in human for CLTX in I/O will be transformative.

CHM-1101 has a unique targeting domain which could very well side step the current burdens of Car-T safely mentioned above. As you say the fact CHM has been invited to present these findings at this prestigious conferences will bring a huge amount of awareness and exposure to these results. And… not one but two slots.

IMU was clever in its ability to garner peer awareness through its conferences. Each time, for example ESMO they expanded on previous presentations from other conferences the further harness the momentum in educating the market. Being cut from the same cloth and with Paul Hoppers extensive feelers we are already seeing the invites coming in. More importantly, due to his ability to secure the licensing for the “good stuff” in the first place.

I see what you did there Stockrock, agreed. Let the results and data do all the speaking and open the doors for you, in presentations that really matter. Otherwise, you are repeating the same thing to the same audience. We will see this data speaking for us in Early November.